Business Context and Reporting Period
This Form 8-K filing by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) reports on the Annual Meeting of Shareholders held on June 18, 2012. The report was filed on June 21, 2012.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Shareholders voted on two primary proposals:
- Proposal 1 (Election of Directors): All seven nominees were elected to serve one-year terms. Significant broker non-votes (24,692,889) were recorded.
- Proposal 2 (Ratification of Auditor): Shareholders approved the selection of ParenteBeard LLC as the independent registered public accounting firm for the year ending December 31, 2012.
| Proposal | For | Against/Withheld | Abstain |
|---|---|---|---|
| Director Election (Total For) | 283,793,965 | 21,275,400 (Withheld) | N/A |
| Auditor Ratification | 64,235,857 | 855,778 | 3,140,469 |
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Important Facts for Investors to Verify
- Verify the high volume of broker non-votes (24,692,889) relative to the total votes cast for the director election.
- Confirm the tenure of the newly elected directors, which expires at the 2013 annual meeting.
- Validate the appointment of ParenteBeard LLC as the independent auditor for the 2012 fiscal year.
- Note the discrepancy between the requested company name (Opus Genetics) and the filing registrant (Rexahn Pharmaceuticals).